Short answer · Medically reviewed summary · Last updated: 2026-04-07
The prevalence of Pulmonary Fibrosis varies significantly by subtype, with Idiopathic Pulmonary Fibrosis (IPF) estimated to affect approximately 14 to 43 per 100,000 individuals globally, though these figures are likely underestimates due to historical diagnostic challenges. Incidence and Demographics Estimating the incidence of Pulmonary Fibrosis is complex, as it encompasses a spectrum of interstitial lung diseases. For IPF, the most common form, incidence rates typically range from 3 to 9 cases per 100,000 person-years.
What is the prevalence of Pulmonary Fibrosis?
Prevalence of Pulmonary Fibrosis: how many people are affected worldwide, differences by sex and region, with sources.
The prevalence of Pulmonary Fibrosis varies significantly by subtype, with Idiopathic Pulmonary Fibrosis (IPF) estimated to affect approximately 14 to 43 per 100,000 individuals globally, though these figures are likely underestimates due to historical diagnostic challenges.
Incidence and Demographics
Estimating the incidence of Pulmonary Fibrosis is complex, as it encompasses a spectrum of interstitial lung diseases. For IPF, the most common form, incidence rates typically range from 3 to 9 cases per 100,000 person-years. Pulmonary Fibrosis is predominantly a disease of aging, with the onset of symptoms most frequently occurring between the ages of 50 and 70. While it is rare in the pediatric population, it can occur in children, often associated with genetic surfactant protein mutations.
Gender, Geography, and Diagnostic Challenges
Data consistently indicates that Pulmonary Fibrosis affects males more frequently than females. While geographic variations exist, some of these differences may reflect disparities in diagnostic access rather than true biological prevalence. A major challenge in determining accurate statistics is that Pulmonary Fibrosis is frequently misdiagnosed as chronic obstructive pulmonary disease (COPD) or asthma in its early stages, leading to significant underreporting in clinical registries.
Real-World Insights
While formal epidemiological studies provide a baseline, patient-driven platforms like DiseaseMaps.org offer vital, complementary insights. Our community of 181 individuals living with Pulmonary Fibrosis helps us understand the lived experience and regional distribution of the condition beyond what is captured in traditional clinical trial data. By aggregating these real-world perspectives, we can better advocate for improved screening and earlier intervention for those affected by this progressive condition.
Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: The portal for rare diseases and orphan drugs
- Pulmonary Fibrosis Foundation (PFF)
